| Document |
Document Title |
|
WO/2020/133012A1 |
The present invention relates to the technical field of herbicide crystallization processes, and specifically relates to a cypyrafluone monoisopropylamine salt and a preparation method and use thereof. The cypyrafluone monoisopropylamine...
|
|
WO/2020/127345A1 |
Compounds of formula (I), as defined herein, to processes for preparing them, to pesticidal, in particular insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to methods of using them to combat and co...
|
|
WO/2020/130214A1 |
The present invention relates to novel hydrazone derivatives with an aryl or heteroaryl group substituted at the terminal amine group thereof and a use thereof.
|
|
WO/2020/132378A2 |
This invention, in at least some embodiments, relates to an inventive molecule, compositions comprising same, and methods of use thereof for treatment of a neurological disorder.
|
|
WO/2020/127685A1 |
The present invention relates to a compound according to formula I (I) and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositio...
|
|
WO/2020/118442A1 |
The invention describes dosing regimens for treating subjects with fibrodysplasia ossificans progressiva characterized by a quiescent period and a non-quiescent period, wherein a therapeutically effective amount of palovarotene is admini...
|
|
WO/2020/122093A1 |
The present invention provides a heterocyclic compound that has orexin 2 receptor agonist activity. Compounds represented by formula (I) and salts thereof have orexin 2 receptor agonist activity and are useful as agents for the prevent...
|
|
WO/2020/118405A1 |
The invention describes dosing regimens for treating subjects with fibrodysplasia ossificans progressiva characterized by a quiescent period and a non-quiescent period, wherein a therapeutically effective amount of palovarotene is admini...
|
|
WO/2020/121326A1 |
The present invention provides an amorphous form of (rac)-tramadol.HCl-celecoxib (1:1) and a solid dispersion and processes for the preparation of the same.
|
|
WO/2020/117493A1 |
A method is disclosed for preparing compounds of Formula 1 by combining compounds of Formulae 2 and 3 and a sulfonyl chloride in a continuous process.
|
|
WO/2020/113816A1 |
Disclosed is an 4-aromatic heterocyclic substituted indazole represented by formula (I) and the use thereof as an IDO/TDO dual inhibitor. The compounds of the present invention have excellent inhibitory effects on both IDO/TDO enzymes an...
|
|
WO/2020/112846A1 |
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a tetrahydroindazole structure which function as modulators (e.g., activators or inhibitors) of sigma-1 ...
|
|
WO/2020/112374A1 |
The compound of formula (I), compositions thereof, processes for their preparation, and their uses as pesticides.
|
|
WO/2020/112581A1 |
Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed h...
|
|
WO/2020/103884A1 |
Amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed ...
|
|
WO/2020/104822A1 |
The present invention relates to a compound of formula (Ia), or a pharmaceutically acceptable salt or hydrate thereof, wherein: the group X-Y is -NHSO2- or -SO2NH-; R1 is H or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is...
|
|
WO/2020/103864A1 |
Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, R1h, L1, L2, L3, Ⓐ, Ⓑ, Ⓒ are as defined as set forth in the specification. Disclosed is compound of formula I f...
|
|
WO/2020/106736A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2019/081573A9 |
A compound of formula (I) or an N-oxide, a salt, a hydrate, a solvate, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer for use in the treatment or prophylaxis of brain ischemia, ischemic...
|
|
WO/2020/103856A1 |
Disclosed are inhibitors of mycobacterial membrane protein MmpL3, compositions comprising the inhibitors, and methods of preparation and use thereof.
|
|
WO/2020/104657A1 |
The present application relates to compounds with NLRP3inhibitory activity and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present application further relates to the use of such compounds in the treatment...
|
|
WO/2020/097012A1 |
Disclosed are compounds of Formula (1), including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein A, Q, R1, R2, R3, R4, W and Y are as defined in the disclosure. Also disclosed are compositions containing...
|
|
WO/2020/093715A1 |
In one aspect relates to the use of an amine compound in a process for the manufacture of a fluorinated or non-fluorinated 5-or 6-membered heterocyclic compound containing two nitrogen atoms in the ring system of the said compound, prefe...
|
|
WO/2020/094440A1 |
The invention relates to a process for the synthesis of aryl hydrazinesof formula I or a salt thereof, which process comprises subjecting an arene of formula II to a coupling reaction with hydrazine or a derivative thereof, wherein the c...
|
|
WO/2020/087565A1 |
The present invention relates to a kinase inhibitor, comprising a compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention further relates to ph...
|
|
WO/2020/092898A1 |
Disclosed are crystalline salts of Compound I, methods of preparing them, and related pharmaceutical preparations thereof. Also disclosed are methods of treatment using the crystalline salts of the invention.
|
|
WO/2020/083377A1 |
The present invention relates to a class of pyrrolidinyl urea derivatives and an application thereof in the preparation of drugs for the treatment of diseases related to TrkA. Specifically disclosed are compounds represented by the formu...
|
|
WO/2020/086728A1 |
In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/082605A1 |
The present invention relates to a pyrazolyl azophenol compound and the synthesis and derivation thereof. Specifically, the compound is 4-((1-methyl-1H-pyrazol-4-yl)diazenyl) phenol, and the structure thereof is as follows: formula I. Th...
|
|
WO/2020/082921A1 |
Provided are a nitrogen heteroaryl amide derivative having the structure of formula (I), a preparation method therefor, and application thereof. Definitions of various substituents are as described in the specification and the claims. Th...
|
|
WO/2020/083733A1 |
The present invention relates to the compounds of formula (I), and the N-oxides, stereoiso- mers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variablesare defined according to the description, (I) Th...
|
|
WO/2020/085504A1 |
A method for producing a compound represented by general formula (I) or a salt thereof by reacting a compound represented by general formula (II) or a salt thereof, with a diazotizing agent and hydrochloric acid, characterized by irradia...
|
|
WO/2020/086533A1 |
The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.
|
|
WO/2020/084094A1 |
The present invention relates to a process for preparing a nitrated compound, comprising the step of reacting a compound (A) comprising at least one substituted or unsubstituted aromatic or heteroaromatic ring, wherein said heteroaromati...
|
|
WO/2020/086732A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/085373A1 |
The present invention provides a novel compound which has activating activity selective for ERβ. A compound represented by formula (1) or a salt thereof. (In the formula, R1 represents a cycloalkyl group having 3-8 carbon atoms, an alke...
|
|
WO/2020/079207A1 |
The present invention relates to processes of preparing N- ((1,2,3,4,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopro
pyl-1H- pyrazole-3-sulfonamide and salts thereof. The present invention further relates to pharmaceutical composition...
|
|
WO/2020/079652A1 |
A DDR1 inhibitor compound can have a structure of Formula A, derivative thereof, prodrug thereof, salt thereof, stereoisomer thereof, tautomer thereof, polymorph thereof, or solvate thereof, or having any chirality at any chiral center, ...
|
|
WO/2020/081381A1 |
Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein...
|
|
WO/2020/081856A1 |
A compound of formula I, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: Formula I wherein X1 is benzimidazolyl, substituted benzimidazolyl, azabenzimidazolyl, substituted azabenzimidazolyl, pyrazolyl, or substi...
|
|
WO/2020/080534A1 |
The present invention provides a method for controlling a plant disease by treating a plant or soil with a compound which has an excellent controlling effect on a plant disease and is represented by formula (I) [in the formula, Z represe...
|
|
WO/2020/079111A1 |
Compounds of the formula (I), wherein the substituents are as defined in claim 1, useful as a pesticides, especially as fungicides.
|
|
WO/2020/072797A1 |
Novel salts of niraparib are provided. Also provided are pharmaceutical compositions comprising those salts, as well as methods and uses pertaining to the same.
|
|
WO/2020/063407A1 |
The present invention relates to general formulas (I) and (II) an N-aromatic amide compound and a preparation method therefor, a pharmaceutical composition and a pharmaceutical preparation containing the general formulas (I) and (II), an...
|
|
WO/2020/065315A1 |
A composition comprising: a compound of formula (I): (I) wherein each of A, B, C and D are independently selected from: C1-18 alkyl; - CCl3; -CF3;C6-12 aryl optionally substituted with C1-18 alkoxy, -CN, -CF3, halogen, NO2, or C1-18 alky...
|
|
WO/2020/069065A1 |
The present disclosure relates to chemical moieties which, when bonded to pharmacophores, cause the pharmacophores to undergo first pass metabolism. By undergoing first pass metabolism, a pharmacophore may be made less bioavailable. Such...
|
|
WO/2020/065323A1 |
Provided is a process for preparing a compound, comprising the steps of a) Reacting a compound of Formula A (Formula A) with the compound 3 (3) to provide the compound 5 (5) or a salt or solvate thereof, wherein R is a linear or branched...
|
|
WO/2020/060092A1 |
The present invention provides a novel prodrug of an edaravone compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same as an active ingredient, and a use thereof in treatment or alleviation of...
|
|
WO/2020/058945A1 |
The present invention is directed to methods of producing substituted pyrazole based compounds through novel intermediates and unique processes for preparing such intermediates which enables synthesis of final product through commerciall...
|
|
WO/2020/056090A1 |
Disclosed are compounds of Formulae 1 and 10 including all geometric and stereoisomers, tautomers, N oxides, and salts thereof, wherein E, L, J, A, T, R1, R2a, R2b, X, Y, R6a, R6b and R29 are as defined in the disclosure. Also disclosed ...
|
